NCT05882032View on ClinicalTrials.gov

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions
HealthyHepatic Insufficiency
Interventions
DRUG

LY3502970

Administered orally.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

78215

Texas Liver Institute, San Antonio

78229

Pinnacle Clinical Research, San Antonio

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05882032 - A Study of LY3502970 in Participants With Impaired and Normal Liver Function | Biotech Hunter | Biotech Hunter